Amgen Manufacturing Ltd – FDA 483, Apr 11, 2019
Amgen Manufacturing Limited in Juncos, PR, a biologic biotech manufacturer, received a Form FDA-483 citing six observations related to significant quality system deficiencies. These issues include inadequate quality control unit procedures, deficient complaint handling, failure to submit biological product deviation reports, insufficient design verification for combination products, and poorly established corrective and preventive action processes, as well as inadequate supplier controls. The observations highlight systemic failures that led to defective auto-injectors and prefilled syringes reaching end-users.
ID · 2151d238-ef8a-48d6-bb0e-e262677fe58d
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.